NEW YORK and LONDON, July 31, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat …
Press Release
Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering
NEW YORK and LONDON, June 28, 2019 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan …
[Read more...] about Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering
Change of AGM Venue on June 27, 2019
Dear Shareholder, We would like to inform shareholders that we shall be unable to hold our forthcoming Annual General Meeting at the place stated in the …
Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)
Part A of a safety and efficacy study successfully completed with nomacopan eye drops which were well tolerated with no serious adverse events. Improvement in …
Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress
Positive initial clinical data reported in ongoing bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) clinical trials Further clinical data from BP …
